In Vitro Combination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2012-08-27

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.01476-12PMID 22926573PMCID PMC3486603
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global tuberculosis control 2010

  2012cited by this paper
• SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis

  2012cited by this paper
• Tuberculosis drugs: new candidates and how to find more.

  2011cited by this paper
• New tuberculosis drugs on the horizon.

  2011cited by this paper
• The TB Alliance: overcoming challenges to chart the future course of TB drug development.

  2011cited by this paper
• Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis

  2010cited by this paper
• In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207

  2010cited by this paper
• Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones

  2010cited by this paper
• Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

  2009cited by this paper
• A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

  2005cited by this paper
• Synergy, antagonism, and what the chequerboard puts between them.

  2003cited by this paper
• Resazurin Microtiter Assay Plate: Simple and Inexpensive Method for Detection of Drug Resistance in Mycobacterium tuberculosis

  2002cited by this paper
• Reproducibility of the microdilution checkerboard method for antibiotic synergy

  1993cited by this paper
• Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

  1992cited by this paper

• Clinical trial of DprE1 inhibitors: from bench to bedside

  2025cites this paper
• Florasulam Is a Potent Inhibitor of Mycobacterium tuberculosis Acetohydroxyacid Synthase and Possesses In Vivo Antituberculosis Activity.

  2025cites this paper
• Bibliometric and Visualization Analysis of DprE1 Inhibitors to Combat Tuberculosis

  2025cites this paper
• Spirocyclic compounds: potential drug leads in the fight against Mycobacterium tuberculosis.

  2025cites this paper
• Antibacterial and antibiofilm activity of ruthenium polypyridine complex against Staphylococcus strains

  2025cites this paper
• SuFEx-based antitubercular compound irreversibly inhibits Pks13

  2025cites this paper
• Minimal Functionalization of Ruthenium Compounds with Enhanced Photoreactivity against Hard-to-Treat Cancer Cells and Resistant Bacteria

  2024cites this paper
• Lippia grata Essential Oil Acts Synergistically with Ampicillin Against Staphylococcus aureus and its Biofilm

  2024cites this paper
• Modulators targeting protein-protein interactions in Mycobacterium tuberculosis.

  2024cites this paper
• Glucose-Binding Dioclea bicolor Lectin (DBL): Purification, Characterization, Structural Analysis, and Antibacterial Properties

  2024cites this paper
• Fate of in vitro cultured Mycobacterium abscessus populations when exposed to moxifloxacin

  2024cites this paper
• Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis

  2024cites this paper
• Polyketide Synthase 13 (Pks13) Inhibition: A Potential Target for New Class of Anti-tubercular Agents.

  2024cites this paper
• Novel Prodrug Strategies for the Treatment of Tuberculosis

  2024cites this paper
• Synthesis of 5-Trifluoromethyl-1,3-thiazin-4-one Compounds using Trifluoromethyl Acrylic Acid as a Synthon.

  2024cites this paper
• Synthesis, structures, reactivity and medicinal chemistry of antitubercular benzothiazinones.

  2023cites this paper
• Whole cell hydride Meisenheimer complex biotransformation guided optimization of antimycobacterial benzothiazinones.

  2023cites this paper
• Effects of benzothiazinone and ethambutol on the integrity of the corynebacterial cell envelope

  2023cites this paper
• Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model

  2023cites this paper
• Targeting polyketide synthase 13 for the treatment of tuberculosis.

  2023cites this paper
• Structural characterization of a galectin from the marine sponge Aplysina lactuca (ALL) with synergistic effects when associated with antibiotics against bacteria.

  2023cites this paper
• Antibacterial and antifungal action of CTAB-containing silica nanoparticles against human pathogens.

  2023cites this paper
• Designing New Magic Bullets to Penetrate the Mycobacterial Shield: An Arduous Quest for Promising Therapeutic Candidates

  2023influential citation
• Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model

  2023cites this paper
• An overview of mechanism and chemical inhibitors of shikimate kinase

  2023cites this paper
• Uncovering interactions between mycobacterial respiratory complexes to target drug-resistant Mycobacterium tuberculosis

  2022cites this paper
• Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine

  2022cites this paper
• The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis

  2022cites this paper
• Chitin Derived Small Molecule AVR-48 Reprograms the Resting Macrophages to an Intermediate Phenotype and Decrease Pseudomonas aeruginosa Mouse Lung Infection

  2022influential citation
• Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis

  2022cites this paper
• NSC19723, a Thiacetazone-Like Benzaldehyde Thiosemicarbazone Improves the Efficacy of TB Drugs In Vitro and In Vivo

  2022cites this paper
• A Hydrazine–Hydrazone Adamantine Compound Shows Antimycobacterial Activity and Is a Probable Inhibitor of MmpL3

  2022cites this paper
• Unraveling the mechanisms of intrinsic drug resistance in Mycobacterium tuberculosis

  2022cites this paper
• Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis

  2022cites this paper
• Mutations in rv0678 confer low-level resistance to benzothiazinone DprE1 inhibitors in M. tuberculosis

  2022cites this paper
• A new exploration toward adamantane derivatives as potential anti‐MDR agents: Design, synthesis, antimicrobial, and radiosterilization activity as potential topoisomerase IV and DNA gyrase inhibitors

  2022influential citation
• Antifungal activity, antibiofilm and synergic effect of diallyl disulfide and diallyl trisulfide against Candida albicans

  2022cites this paper
• Implications of Mycobacterium tuberculosis Metabolic Adaptability on Drug Discovery and Development.

  2022cites this paper
• The biofilm inhibition activity of a NO donor nanosilica with enhanced antibiotics action.

  2021cites this paper
• Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review

  2021cites this paper
• Tuberculosis: current scenario, drug targets, and future prospects

  2021cites this paper
• 8-cyanobenzothiazinone analogs with potent antitubercular activity

  2021cites this paper
• Insights into development of Decaprenyl-phosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitors as antitubercular agents: A state of the art review.

  2021cites this paper
• Synthesis and evaluation of thiophene based small molecules as potent inhibitors of Mycobacterium tuberculosis.

  2020cites this paper
• Tuberculosis - present medication and therapeutic prospects.

  2020cites this paper
• Molecule Property Analyses of Active Compounds for Mycobacterium Tuberculosis.

  2020cites this paper
• Основные результаты клинических исследований эффективности, безопасности и фармакокинетики перспективного противотуберкулезного препарата макозинон (PBTZ169)

  2020cites this paper
• [The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone (PBTZ169)].

  2020cites this paper
• Minimum Bactericidal Concentration Techniques in Mycobacterium tuberculosis: A Systematic Review

  2020cites this paper
• New tuberculosis drug targets, their inhibitors and potential therapeutic impact.

  2020cites this paper
• Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs

  2020influential citation
• Handling the Hurdles on the Way to Anti-tuberculosis Drug Development

  2020cites this paper
• Nutritional, phytoconstituents, and free radical scavenging potentials of Cola lepidota K. Schum. and Irvingia gabonensis (Aubry-Lecomte ex O'Rorke) Baill. leaves

  2020cites this paper
• In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against Mycobacterium tuberculosis.

  2020cites this paper
• Malaria and tuberculosis as diseases of neglected populations: state of the art in chemotherapy and advances in the search for new drugs

  2020cites this paper
• In vitro interaction profiles of new anti-TB drugs Bedaquiline, Delamanid with Moxifloxacin against clinical isolates of Mycobacterium tuberculosis.

  2019cites this paper
• 4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB.

  2019cites this paper
• What is New in Management of Pediatric Tuberculosis ?

  2019cites this paper
• Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo

  2019cites this paper
• Evaluation of the antimicrobial activity of Cinnamomum zeylanicum essential oil and trans-Cinnamaldehyde against resistant Mycobacterium tuberculosis

  2019cites this paper
• Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma

  2019cites this paper
• Targeting extracellular glycans: tuning multimeric boronic acids for pathogen-selective killing of Mycobacterium tuberculosis

  2019cites this paper
• Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of M. tuberculosis to bedaquiline

  2019influential citation
• Decoding the signature of molecular mechanism involved in mutation associated resistance to 1, 3-benzothiazin-4-ones (Btzs) based DprE1 inhibitors using BTZ043 as a reference drug

  2019cites this paper
• Dimeric benzoboroxoles for targeted activity against Mycobacterium tuberculosis.

  2019cites this paper
• New Drugs for the Treatment of Tuberculosis.

  2019cites this paper
• Prevention and treatment of tuberculosis in solid organ transplant recipients

  2019cites this paper
• Synthesis and cytotoxic activity against human tumor cells of heterocyclic systems derived from 2‐thioxo‐1,2‐dihydro‐4 H ‐3,1‐benzothazin‐4‐one

  2019cites this paper
• Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)

  2018cites this paper
• Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis

  2018influential citation
• Drug-resistant tuberculosis in France : epidemiology and management

  2018cites this paper
• Efficacy of modified Leeming-Notman media in a resazurin microtiter assay in the evaluation of in-vitro activity of fluconazole against Malassezia furfur ATCC 14521.

  2018cites this paper
• Cell envelope lipids in the pathophysiology of Mycobacterium tuberculosis.

  2018cites this paper
• Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.

  2018cites this paper
• Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery

  2018cites this paper
• Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis

  2018cites this paper
• Deconvolution of Mycobacterium tuberculosis drug targets using high throughput screening approaches

  2018cites this paper
• Therapeutic potential of promiscuous targets in Mycobacterium tuberculosis

  2018cites this paper
• The Antituberculosis Drug Ethambutol Selectively Blocks Apical Growth in CMN Group Bacteria

  2017cites this paper
• Identification of the anti‐mycobacterial functional properties of piperidinol derivatives

  2017influential citation
• Azoreductases in drug metabolism

  2017cites this paper
• Cell wall remodeling proteins in Mycobacterium tuberculosis : structure, function and inhibition

  2017cites this paper
• Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13

  2017cites this paper
• News on therapeutic management of MDR-tuberculosis: a literature review

  2017cites this paper
• A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells

  2017cites this paper
• Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis.

  2017cites this paper
• Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro

  2017cites this paper
• Tuberculosis: Still a Way to go Ahead for a Lead- A Review

  2017influential citation
• Synthetic investigational new drugs for the treatment of tuberculosis

  2016cites this paper
• New derivative of 2-(2,4-dihydroxyphenyl)thieno-1,3-thiazin-4-one (BChTT) elicits antiproliferative effect via p38-mediated cell cycle arrest in cancer cells.

  2016cites this paper
• Biochemical and drug targeting studies of Mycobacterium tuberculosis cholesterol oxidase P450 enzymes

  2016cites this paper
• Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis

  2016cites this paper
• Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis

  2016cites this paper
• A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of Action

  2016cites this paper
• Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins.

  2016cites this paper
• Simple fluorescence‐based high throughput cell viability assay for filamentous fungi

  2015cites this paper
• benzothiazinones against Mycobacterium tuberculosis

  2015cites this paper
• Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.

  2015cites this paper
• Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.

  2015cites this paper
• Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

  2015cites this paper